The global point-of-care testing (POCT) market is driven by rising patient demand, technological innovation, and supportive regulatory frameworks. Rapid diagnostics, enhanced chronic disease ...

WALTHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (LMDX), a next-generation point of care diagnostics company, today announced findings from its second annual “Point of Care ...

Point-of-care-testing for suspected COVID-19 reduces time to results and may improve infection control, suggesting these tests might have clinical advantages over widely used laboratory PCR methods.

Large scale deployment of rapid, low-cost, hand-held point of care testing devices for diagnosing infectious diseases is critical for improving global health. Recent advances in engineering and ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy To put it another way ...

This presentation will briefly cover point-of-care testing (POCT) from a historical standpoint. (What are we doing and why did we decide to do it this way?) This presentation will incorporate ...

The healthcare world is witnessing a quiet revolution in diagnostic testing. Point-of-care testing with dry chemistry methods isn't just another technological advancement - it's changing the game ...

Point-of-care testing (POCT) is growing in popularity as a means of delivering faster turnaround time of test results closer to the patient. This session will review the latest recommendations and ...

LumiraDx shares these and other findings from its second annual U.S. survey “Point of Care Diagnostics: A Clinician's View” WALTHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: ...